Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

Listed in the December 27, 2023 extract; not in the current extract (Aug 26, 2026): Lodalis (02432463). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-08-26.xml.

COLESEVELAM HYDROCHLORIDE

2 general benefit · 1 listing conditions apply

Other products in the same Health Canada class (C10A, C10AC) — coverage varies; not interchangeable

  • Cholestyramine resin (Questran Light 4g Pk): general benefit, Not a benefit
  • Atorvastatin (Lipitor): general benefit
  • Bezafibrate (Bezalip): general benefit
  • Fenofibrate (Lipidil): general benefit, Not a benefit
  • Fluvastatin (Lescol): general benefit, Not a benefit
  • Gemfibrozil (Lopid): general benefit, Not a benefit

9 more in the class list below

Apo-Colesevelam · DIN 02494051 · 625mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Colesevelam · DIN 02494051 Manufacturer: Apotex Inc.; listing date 2022-01-31 Health Canada: Marketed since 2020-07-23 · brand APO-COLESEVELAM · ATC C10AC04 COLESEVELAM · form Tablet · route Oral · ingredients COLESEVELAM HYDROCHLORIDE 625 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Colesevelam: Formulary list price $0.5931/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.5931 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98409 · Verify on the e-Formulary ↗ (DIN 02494051)

Source record
DIN 02494051: Apo-Colesevelam Raw flags: chronicUseMed=Y, sec3=Y Item: 240600072; group id 300; item number 0653; lccId None; manufacturer id APX Source form: Tab; strength: 625mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.5931; ministry $0.5931 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02494051 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98409 Therapeutic Notes (formulary) Colesevelam Hydrochloride is indicated for the reduction of cholesterol blood level in patients with hypercholesterolemia (Frederickson Type IIa) as an adjunct to diet and lifestyle changes, when the response to these measures has been inadequate, in patients: . who are not adequately controlled with an HMG-CoA reductase inhibitor (statin) alone, or . who are unable to tolerate a statin.
Interchangeable products
Lodalis · DIN 02373955 · $0.5931
Shortage status: resolved shortage (ended 2024-06-26); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02494051
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lodalis · DIN 02373955 · 625mg · tablet

General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Lodalis · DIN 02373955 Manufacturer: Valeant Canada Ltd.; listing date 2014-05-29 Health Canada: Marketed since 2020-12-09 · brand LODALIS · ATC C10AC04 COLESEVELAM · form Tablet · route Oral · ingredients COLESEVELAM HYDROCHLORIDE 625 MG · company Bausch health, canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.5931 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85917 · Verify on the e-Formulary ↗ (DIN 02373955)

Source record
DIN 02373955: Lodalis Raw flags: chronicUseMed=Y, sec3=Y Item: 240600072; group id 300; item number 0653; lccId None; manufacturer id VAL Source form: Tab; strength: 625mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.4184; ministry $0.5931 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02373955 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85917 Therapeutic Notes (formulary) Colesevelam Hydrochloride is indicated for the reduction of cholesterol blood level in patients with hypercholesterolemia (Frederickson Type IIa) as an adjunct to diet and lifestyle changes, when the response to these measures has been inadequate, in patients: . who are not adequately controlled with an HMG-CoA reductase inhibitor (statin) alone, or . who are unable to tolerate a statin.
Interchangeable products
Apo-Colesevelam · DIN 02494051 · $0.5931
Shortage status: resolved shortage (ended 2024-03-25); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02373955
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Colesevelam · PIN 09858334 · 625mg · tablet

Temporary benefitOntario PIN; no Health Canada record under this code
StatusTemporary benefit
Write on scriptcheck temporary-benefit rules below
Patient paysPatient pays: program not supplied; amount cannot be determined.

No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Check Health Canada brand search
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Colesevelam · DIN 09858334 Manufacturer: Glenmark Pharmaceuticals Canada Inc.; listing date 2024-04-30 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Check this DIN again

Colesevelam: Formulary list price $0.5931/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.5931 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 09858334)

Source record
DIN 09858334: Colesevelam Raw flags: chronicUseMed=Y, sec3c=Y Item: 240600077; group id 300; item number 0654; lccId None; manufacturer id GLP Source form: Tab; strength: 625mg Recorded listing: Temporary benefit (shortage substitute); chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.5931; ministry $0.5931 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=09858334 Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp Therapeutic Notes (formulary) Colesevelam Hydrochloride is indicated for the reduction of cholesterol blood level in patients with hypercholesterolemia (Frederickson Type IIa) as an adjunct to diet and lifestyle changes, when the response to these measures has been inadequate, in patients: . who are not adequately controlled with an HMG-CoA reductase inhibitor (statin) alone, or . who are unable to tolerate a statin.
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=09858334
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (24:06 Antilipemic Drugs) and how they are covered

Matched class: 24:06 Antilipemic Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: AMLODIPINE BESYLATE & ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, BEZAFIBRATE, ROSUVASTATIN CALCIUM Some products covered without a code (check the product listing): CHOLESTYRAMINE RESIN, FENOFIBRATE, FLUVASTATIN SODIUM, GEMFIBROZIL, LOVASTATIN, PRAVASTATIN SODIUM, SIMVASTATIN 24:00 CARDIOVASCULAR DRUGS

INCLISIRAN

· 1 products · Limited Use, codes 732 · strengths: 284mg/1.5mL · Inj Sol-1.5mL Pref Syr Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:00 24:06 Antilipemic Drugs

CHOLESTYRAMINE RESIN

· 4 products · Listed, not a benefit (1), General benefit (3) · strengths: · Oral Pd-Pouch Pk

ATORVASTATIN CALCIUM

· 99 products · General benefit · strengths: 10mg, 20mg, 40mg, 80mg · Tab

BEZAFIBRATE

· 2 products · General benefit · strengths: 400mg · SR Tab

FENOFIBRATE

· 16 products · Listed, not a benefit (2), General benefit (9), Off-Formulary Interchangeable, not an ODB benefit (5) · strengths: 100mg, 67mg, 200mg, 160mg, 48mg, 145mg · Cap, Tab

FLUVASTATIN SODIUM

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 20mg, 40mg, 80mg · Cap, ER Tab

GEMFIBROZIL

· 6 products · Listed, not a benefit (1), General benefit (2), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 300mg, 600mg · Cap, Tab

LOVASTATIN

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 20mg, 40mg · Tab

PRAVASTATIN SODIUM

· 57 products · Listed, not a benefit (3), General benefit (54) · strengths: 10mg, 20mg, 40mg · Tab

ROSUVASTATIN CALCIUM

· 80 products · General benefit · strengths: 5mg, 10mg, 20mg, 40mg · Tab

SIMVASTATIN

· 73 products · Listed, not a benefit (5), General benefit (68) · strengths: 5mg, 10mg, 20mg, 40mg, 80mg · Tab

EVOLOCUMAB

· 1 products · Limited Use, codes 527, 737 · strengths: 140mg/mL · Inj Sol-Pref Syr Autoinj Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:06 and 4 more
Full class listing Related classes: 24:04 Cardiac Drugs, 24:08 Hypotensive Drugs (For Diuretics See 40:28), 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE LODALIS (colesevelam) is indicated for the reduction of cholesterol blood level in patients with hypercholesterolemia (Fredrickson Type IIa) as an adjunct to diet and lifestyle changes, when the response to these measures has been inadequate, in patients:  who are not adequately controlled with an HMG-CoA reductase inhibitor (statin) alone, or  who are unable to tolerate a statin. Limitations of Use LODALIS (colesevelam) has not been studied in Fredrickson Type I, IIb, III, IV and V dyslipidemias. Geriatrics (≥65 years of age) There is no need for dose adjustment when LODALIS is administered to elderly patients. Pediatrics (<18 years of age) The safety and efficacy of LODALIS have not been established in children and adolescent patients; therefore, the use of LODALIS in these patient populations is not recommended. Pr LODALISTM Product Monograph Page 3 of 31 https://pdf.hres.ca/dpd_pm/00059185.PDF PM date: December 4, 2020 Source product: LODALIS; DIN 02373955; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.